Literature DB >> 19629644

Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth.

Dan Zhu1, Jennifer Hensel, Robert Hilgraf, Mahan Abbasian, Owen Pornillos, Gordafaried Deyanat-Yazdi, Xuequn Helen Hua, Sarah Cox.   

Abstract

Protein kinase CK2 (CK2) is a highly conserved and ubiquitous serine/threonine kinase. It is a multifunctional and pleiotropic protein kinase implicated in the regulation of cell proliferation, survival, and differentiation. Deregulation of CK2 is observed in a wide variety of tumors. It has been the focus of intensive research efforts to establish the cause-effect relationship between CK2 and neoplastic growth. Here, we further validate the role of CK2 in cancer cell growth using siRNA approach. We also screened a library of more than 200,000 compounds and identified several molecules, which inhibit CK2 with IC(50) < 1 microM. The binding mode of a representative compound with maize CK2 was determined. In addition, the cellular activity of the compounds was demonstrated by their inhibition of phosphorylation of PTEN Ser370 in HCT116 cells. Treatment of a variety of cancer cell lines with the newly identified CK2 inhibitor significantly blocked cell growth with IC(50)s as low as 300 nM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629644     DOI: 10.1007/s11010-009-0216-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  66 in total

Review 1.  Casein kinase 2: an 'eminence grise' in cellular regulation?

Authors:  L A Pinna
Journal:  Biochim Biophys Acta       Date:  1990-09-24

2.  CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation.

Authors:  Kazuhiko Yamane; Timothy J Kinsella
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

Review 3.  Casein kinase I and II--multipotential serine protein kinases: structure, function, and regulation.

Authors:  P T Tuazon; J A Traugh
Journal:  Adv Second Messenger Phosphoprotein Res       Date:  1991

Review 4.  CK2 as a positive regulator of Wnt signalling and tumourigenesis.

Authors:  David C Seldin; Esther Landesman-Bollag; Marganit Farago; Nicolas Currier; David Lou; Isabel Dominguez
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

5.  Inducible expression of the regulatory protein kinase CK2beta subunit: incorporation into complexes with catalytic CK2 subunits and re-examination of the effects of CK2beta on cell proliferation.

Authors:  G Vilk; D R Derksen; D W Litchfield
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

6.  Casein kinase 2 regulates both apoptosis and the cell cycle following DNA damage induced by 6-thioguanine.

Authors:  Kazuhiko Yamane; Timothy J Kinsella
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

7.  Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

Authors:  Joel W Slaton; Gretchen M Unger; Daniel T Sloper; Alan T Davis; Khalil Ahmed
Journal:  Mol Cancer Res       Date:  2004-12       Impact factor: 5.852

8.  The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development.

Authors:  David Y Lou; Isabel Dominguez; Paul Toselli; Esther Landesman-Bollag; Conor O'Brien; David C Seldin
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

9.  The selectivity of inhibitors of protein kinase CK2: an update.

Authors:  Mario A Pagano; Jenny Bain; Zygmunt Kazimierczuk; Stefania Sarno; Maria Ruzzene; Giovanni Di Maira; Matthew Elliott; Andrzej Orzeszko; Giorgio Cozza; Flavio Meggio; Lorenzo A Pinna
Journal:  Biochem J       Date:  2008-11-01       Impact factor: 3.857

10.  Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.

Authors:  Zhe Nie; Carin Perretta; Philip Erickson; Stephen Margosiak; Jia Lu; April Averill; Robert Almassy; Shaosong Chu
Journal:  Bioorg Med Chem Lett       Date:  2007-11-28       Impact factor: 2.823

View more
  12 in total

1.  Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.

Authors:  Fabrice Pierre; Peter C Chua; Sean E O'Brien; Adam Siddiqui-Jain; Pauline Bourbon; Mustapha Haddach; Jerome Michaux; Johnny Nagasawa; Michael K Schwaebe; Eric Stefan; Anne Vialettes; Jeffrey P Whitten; Ta Kung Chen; Levan Darjania; Ryan Stansfield; Joshua Bliesath; Denis Drygin; Caroline Ho; May Omori; Chris Proffitt; Nicole Streiner; William G Rice; David M Ryckman; Kenna Anderes
Journal:  Mol Cell Biochem       Date:  2011-07-14       Impact factor: 3.396

2.  Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.

Authors:  Andriy G Golub; Volodymyr G Bdzhola; Yaroslav V Kyshenia; Vladislav M Sapelkin; Andriy O Prykhod'ko; Olexander P Kukharenko; Olga V Ostrynska; Sergiy M Yarmoluk
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

3.  Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Authors:  Janeen H Trembley; Gretchen M Unger; Vicci L Korman; Diane K Tobolt; Zygmunt Kazimierczuk; Lorenzo A Pinna; Betsy T Kren; Khalil Ahmed
Journal:  Cancer Lett       Date:  2011-10-12       Impact factor: 8.679

4.  Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Authors:  Janeen H Trembley; Gretchen M Unger; Omar Cespedes Gomez; J Abedin; Vicci L Korman; Rachel I Vogel; Gloria Niehans; Betsy T Kren; Khalil Ahmed
Journal:  Mol Cell Pharmacol       Date:  2014

5.  CK2α is essential for embryonic morphogenesis.

Authors:  Isabel Dominguez; Irene R Degano; Kathleen Chea; Julie Cha; Paul Toselli; David C Seldin
Journal:  Mol Cell Biochem       Date:  2011-07-15       Impact factor: 3.396

6.  The cytosolic protein kinase CK2 phosphorylates cardiac calsequestrin in intact cells.

Authors:  Timothy P McFarland; Naama H Sleiman; Daniel B Yaeger; Steven E Cala
Journal:  Mol Cell Biochem       Date:  2011-03-23       Impact factor: 3.396

7.  Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.

Authors:  Laszlo Gyenis; James S Duncan; Jacob P Turowec; Maria Bretner; David W Litchfield
Journal:  J Proteome Res       Date:  2011-10-13       Impact factor: 4.466

8.  Overexpression of PTEN suppresses lipopolysaccharide-induced lung fibroblast proliferation, differentiation and collagen secretion through inhibition of the PI3-K-Akt-GSK3beta pathway.

Authors:  Zhengyu He; Yuxiao Deng; Wen Li; Yongming Chen; Shunpeng Xing; Xianyuan Zhao; Jia Ding; Yuan Gao; Xiangrui Wang
Journal:  Cell Biosci       Date:  2014-01-06       Impact factor: 7.133

9.  Association of protein kinase CK2 inhibition with cellular radiosensitivity of non-small cell lung cancer.

Authors:  Qianwen Li; Ke Li; Tianyang Yang; Sheng Zhang; Yu Zhou; Zhenyu Li; Jinrong Xiong; Fangzheng Zhou; Xiaoshu Zhou; Li Liu; Rui Meng; Gang Wu
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

10.  More precise prediction in Chinese patients with penile squamous cell carcinoma: protein kinase CK2α catalytic subunit (CK2α) as a poor prognosticator.

Authors:  Zai-Shang Li; Chuang-Zhong Deng; Yun-Lin Ye; Kai Yao; Sheng-Jie Guo; Jie-Ping Chen; Yong-Hong Li; Zi-Ke Qin; Zhuo-Wei Liu; Bin Wang; Qi Zhao; Peng Chen; Qi-Wu Mi; Xiao-Feng Chen; Hui Han; Fang-Jian Zhou
Journal:  Oncotarget       Date:  2017-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.